ASCO® 2026: Four trends reshaping oncology commercialization

New therapies, new biomarkers, and expanding real-world data are creating unprecedented opportunities, but they’re also increasing the complexity of bringing oncology innovations to market. So how do organizations keep pace? Drawing on themes discussed in our recent ASCO® webinar, Inizio Ignite‘s Head of Data & AI, Jo Ann Saitta, explains why the competitive advantage no longer comes from having more data, but from turning it into faster, smarter commercial decisions.

What ASCO® 2026 means for oncology commercialization

The incredible scientific advances at ASCO® 2026 were inspiring. A number of themes stood out across the exhibition floor and plenary sessions:

1. Oncology innovation is outpacing commercial decision making

There are more targets, more lines of therapy and more treatment decisions than ever before. As oncology portfolios become increasingly specialized, commercial teams need to keep pace with rapidly evolving clinical evidence, competitive activity, and changing HCP needs.

 2. Why fragmented data delays patient identification and access

Piecing together all the information about patients and their journeys through a variety of different datasets is hugely challenging.

 3. AI delivers value only when paired with oncology expertise

This was the year ASCO® saw AI move from the podium and into commercial decision making. But that decision making still has to be done by domain experts. But that decision making still has to be done by domain experts. This underpins the foundation of our approach to Intelligent Commercialization™ at Inizio.

4. Commercial speed is the new differentiator

Making decisions in weeks rather than months is the new norm, and the teams that lag are losing market share.

Turning data into competitive advantage

Identifying patients earlier and helping them reach the right treatments sooner was one of the biggest takeaways from ASCO® from a data and AI perspective. Achieving that starts by identifying the right patients using data signals and a deeper understanding of treatment pathways, helping get them onto the right therapies sooner.

It’s then about personalization, whether that’s targeting specific patients or HCPs across different channels, regions, and messages. This doesn’t mean averages or aggregates; it means individual-level, de-identified patient data that allow organizations to personalize engagement and use micro-segmentation.

This level of speed and personalization depends on one capability: transforming fragmented real-world data into connected commercial intelligence.

These four trends aren’t happening in isolation. More therapies and biomarkers create greater commercial complexity, which in turn generates more data and more decisions. Success depends on connecting these data signals quickly enough to make faster, smarter commercial decisions.

Making faster, confident decisions across the lifecycle

At Inizio, our experts help organizations turn fragmented real-world data into connected commercial intelligence through DataGateway. This enables organizations to identify patients earlier, uncover new commercial opportunities, and make faster, more confident decisions across the product lifecycle.

Across the commercialization lifecycle, connected data intelligence supports better decisions at every stage:

• Pre-launch: Identify the right patients, HCPs, and influencers earlier.
• Launch: Optimize omnichannel engagement and commercial execution.
• Post-launch: Measure changes in HCP behavior, patient access, and commercial performance.

 Delivering measurable commercial impact

The value of this approach is already being seen in practice.

For one oncology client, we used DataGateway to create an oncology marketing intelligence system. It brought datasets together to offer a clearer view of patients and their friction points, unlocking almost $50m in quarterly revenue that was previously miscounted, misattributed, or simply invisible. It also saved the client around $1.5m a year, cut their data team’s analytics workload by 50%, and accelerated insight generation from an unacceptable four months to just one.

ASCO® 2026 made one thing clear: oncology innovation isn’t slowing down. As new therapies, biomarkers, and treatment pathways continue to emerge, commercial complexity will only increase.

The organizations best positioned to succeed won’t simply have access to more data. They’ll be the ones that can combine connected data, AI, and domain expertise to make faster, smarter decisions – from identifying patients earlier to optimizing engagement throughout the commercialization journey.

Let’s discuss your oncology commercialization challenges

This article is based on our webinar, Smarter science, sharper strategy: Expert perspectives from ASCO® 2026. Watch the on-demand recording to hear our experts explore these themes in more depth, including the scientific breakthroughs, commercialization challenges, and practical lessons emerging from this year’s congress. Or, if you’d like to discuss your own commercialization challenges or learn more about DataGateway, get in touch with our team.